REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/10/2025
Back to search
Official data from USPTO
F
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
03/10/2025
Trademark type
Combined
Nice classes
1, 5, 9, 42
Filing date
07/06/2018
Registration date
03/10/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/10/2020
Last transaction
03/10/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
11/19/2019
First use in commerce
11/19/2019
Drawing code
5
Owner type
16
Owner location
Cambridge, MA
Examiner
BRADLEY, EVELYN
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized "F' design.
Holders and representatives
Holders
Factor Bioscience LLC
Representatives
RACHELLE A. DUBOW, ESQ. MORGAN, LEWIS & BOCKIUS LLP
Technical classification
Nice Classes
Class 1Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleaseszinc-finger nucleasesmeganucleasesnickasestranscription activator-like effector nucleases for use in vivo and in vitro genetic engineering
Class 5
Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseasesinfectious diseasesvitamin B12 deficiencydegenerative joint diseasessensory organ diseaseshereditary diseasesgenetic diseases in the nature of chromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injurypsychological diseases and physiological diseases in the nature of heart disease; gene therapy productsgenetically engineered cells and tissues for medical purposesspecifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy productspharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factorspharmaceutical preparations for use in cell therapy for treatment of wounded skincancerchromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injuryheart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cellswith or without gene-editingfor treatment of wounded skincancerchromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injuryheart disease
Class 9
Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy productscell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNAcell-culture instruments in the nature of cell incubatorscell transfection instrumentscell imaging instruments
Class 42
Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapieswith or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field ofgene editingmRNA engineeringcell reprogramming and cell therapy development; scientific laboratory servicesin the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cellswith or without gene-editing; scientific laboratory services in the field of gene-editing
Publications
History of USPTO decisions and trademark events.
30 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/10/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/05/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/04/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/29/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/29/2019
IUAF
USE AMENDMENT FILED
12/18/2019
EISU
TEAS STATEMENT OF USE RECEIVED
12/18/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/13/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/18/2019
PUBO
PUBLISHED FOR OPPOSITION
06/18/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/29/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/10/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
05/09/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/09/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
05/09/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/09/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/10/2019
GNFR
FINAL REFUSAL E-MAILED
04/10/2019
CNFR
FINAL REFUSAL WRITTEN
04/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/19/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/19/2019
ALIE
ASSIGNED TO LIE
02/18/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/27/2018
GNRT
NON-FINAL ACTION E-MAILED
10/27/2018
CNRT
NON-FINAL ACTION WRITTEN
10/27/2018
DOCK
ASSIGNED TO EXAMINER
10/25/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/12/2018
NWAP
NEW APPLICATION ENTERED
07/10/2018
Continuous trademark protection
Get notified about every new filing that threatens F or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.